LEO LUZNIK to Myeloablative Agonists
This is a "connection" page, showing publications LEO LUZNIK has written about Myeloablative Agonists.
Connection Strength
1.013
-
Randomized Phase III BMT CTN Trial of Calcineurin Inhibitor-Free Chronic Graft-Versus-Host Disease Interventions in Myeloablative Hematopoietic Cell Transplantation for Hematologic Malignancies. J Clin Oncol. 2022 02 01; 40(4):356-368.
Score: 0.687
-
Multi-institutional study of post-transplantation cyclophosphamide as single-agent graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation using myeloablative busulfan and fludarabine conditioning. J Clin Oncol. 2014 Nov 01; 32(31):3497-505.
Score: 0.104
-
Experts' considerations on HLA-haploidentical stem cell transplantation. Eur J Haematol. 2014 Sep; 93(3):187-97.
Score: 0.101
-
Outcomes of related donor HLA-identical or HLA-haploidentical allogeneic blood or marrow transplantation for peripheral T cell lymphoma. Biol Blood Marrow Transplant. 2013 Apr; 19(4):602-6.
Score: 0.093
-
Adoptive transfer of activated marrow-infiltrating lymphocytes induces measurable antitumor immunity in the bone marrow in multiple myeloma. Sci Transl Med. 2015 May 20; 7(288):288ra78.
Score: 0.027